{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:27Z","timestamp":1781254587182,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008149","name":"Royal College of Pathologists of Australasia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.013","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:36:20Z","timestamp":1774035380000},"page":"e723-e729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-1940","authenticated-orcid":false,"given":"Aditya","family":"Tedjaseputra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-8155","authenticated-orcid":false,"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.03.013_bib0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0002","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0003","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc840","article-title":"Core-binding factors in haematopoiesis and leukaemia","volume":"2","author":"Speck","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2026.03.013_bib0004","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.03.013_bib0005","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2026.03.013_bib0006","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1007\/s00432-022-04356-9","article-title":"Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry","volume":"149","author":"Hanoun","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400326","article-title":"Intermediate-dose cytarabine as postinduction AML therapy","volume":"4","author":"Hunault","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clml.2026.03.013_bib0008","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41409-024-02373-5","article-title":"Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT","volume":"59","author":"Al Hamed","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.03.013_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2021.278645","article-title":"Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study","volume":"107","author":"Kayser","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.013_bib0010","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.013_bib0011","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.03.013_bib0012","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 Update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0013","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.013_bib0014","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.013_bib0015","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0016","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0017","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0018","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3324\/haematol.2019.235721","article-title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia","volume":"106","author":"Puckrin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.013_bib0019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood.2024024264","article-title":"Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML","volume":"144","author":"Cook","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0020","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1182\/bloodadvances.2025017244","article-title":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML","volume":"9","author":"Russell","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.013_bib0021","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.clml.2026.03.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-1719","article-title":"Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: a subanalysis from the pethema quiwi trial","volume":"146","author":"Sargas","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-456","article-title":"Frequency and impact of FLT3-ITD microclones in younger AML patients","volume":"146","author":"Duployez","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0024","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.013_bib0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in Acute myeloid Leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.013_bib0026","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.013_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70198","article-title":"A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 (mut) AML in MRD(neg) remission after intensive induction","volume":"9","author":"Dohner","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.03.013_bib0028","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0029","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0030","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.013_bib0031","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.013_bib0032","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2025-345","article-title":"FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: analysis of the UK NCRI AML17 and AML19 trials","volume":"146","author":"Tedjaseputra","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0034","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","article-title":"Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia","volume":"6","author":"Wakita","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.013_bib0035","article-title":"Location, location, location: a mini-review of CEBPA variants in patients with acute myeloid leukemia","volume":"20","author":"Faisal","year":"2023","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2026.03.013_bib0036","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0037","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1002\/hem3.141","article-title":"Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA","volume":"8","author":"Vonk","year":"2024","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.03.013_bib0038","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10428194.2019.1576868","article-title":"Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations","volume":"60","author":"Deng","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.03.013_bib0039","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.013_bib0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:06:13Z","timestamp":1781251573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000765"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}